Amedisys Inc (NASDAQ:AMED) Director Jake L. Netterville sold 3,394 shares of the firm’s stock in a transaction on Friday, November 16th. The stock was sold at an average price of $122.86, for a total value of $416,986.84. Following the transaction, the director now directly owns 75,266 shares of the company’s stock, valued at $9,247,180.76. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of AMED opened at $119.82 on Thursday. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.06 and a quick ratio of 1.06. The stock has a market capitalization of $3.73 billion, a PE ratio of 54.22, a PEG ratio of 1.74 and a beta of 1.22. Amedisys Inc has a one year low of $49.80 and a one year high of $128.59.

Amedisys (NASDAQ:AMED) last issued its earnings results on Monday, October 29th. The health services provider reported $0.95 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.18. The company had revenue of $417.34 million during the quarter, compared to the consensus estimate of $411.05 million. Amedisys had a return on equity of 23.27% and a net margin of 5.39%. The firm’s revenue for the quarter was up 11.7% compared to the same quarter last year. During the same period last year, the business posted $0.56 EPS. On average, sell-side analysts forecast that Amedisys Inc will post 3.58 earnings per share for the current fiscal year.

Several research firms have recently weighed in on AMED. Royal Bank of Canada lifted their price objective on Amedisys to $115.00 and gave the stock an “outperform” rating in a research report on Friday, August 3rd. SunTrust Banks lifted their price objective on Amedisys to $130.00 and gave the stock a “buy” rating in a research report on Thursday, October 11th. Benchmark raised Amedisys from a “hold” rating to a “buy” rating and set a $125.00 price objective for the company in a research report on Tuesday, October 30th. UBS Group began coverage on Amedisys in a research report on Friday, November 16th. They issued a “neutral” rating and a $126.00 price objective for the company. Finally, Cantor Fitzgerald began coverage on Amedisys in a research report on Thursday, September 13th. They issued a “neutral” rating and a $117.00 price objective for the company. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. Amedisys presently has a consensus rating of “Buy” and a consensus price target of $107.08.

Institutional investors and hedge funds have recently modified their holdings of the company. Itau Unibanco Holding S.A. acquired a new stake in shares of Amedisys in the 2nd quarter valued at about $149,000. Moneta Group Investment Advisors LLC acquired a new stake in shares of Amedisys in the 2nd quarter valued at about $181,000. Cubist Systematic Strategies LLC grew its stake in shares of Amedisys by 1,086.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 2,372 shares of the health services provider’s stock valued at $203,000 after buying an additional 2,172 shares during the period. Dorsey & Whitney Trust CO LLC acquired a new stake in shares of Amedisys in the 3rd quarter valued at about $203,000. Finally, Ibex Investors LLC acquired a new stake in shares of Amedisys in the 3rd quarter valued at about $215,000. Institutional investors own 90.05% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Amedisys Inc (AMED) Director Sells $416,986.84 in Stock” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/11/22/amedisys-inc-amed-director-sells-416986-84-in-stock.html.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Featured Article: Terms to Better Understand Call Options

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.